Rainard Fuhr

2.0k citations

57 papers · 1.5k indexed · 1 hit paper · h-index 21

Immunology top 5%
- Biosimilars and Bioanalytical Methods 9
Physiology top 10%
- Asthma and respiratory diseases 20
Immunology and Allergy top 10%
- Allergic Rhinitis and Sensitization 6
Pulmonary and Respiratory Medicine top 10%
- Respiratory and Cough-Related Research 10
- Inhalation and Respiratory Drug Delivery 7
- Chronic Obstructive Pulmonary Disease (COPD) Research 5
Infectious Diseases top 10%
Pediatrics, Perinatology and Child Health
- Pharmaceutical studies and practices 8
Animal Science and Zoology
- Pharmacological Effects and Assays 5

Co-authors: James D. Thompson Tal Zaks Hari Pujar Mike Smith Lori Panther Igor Smolenov Michael Watson Joseph J. Senn
Cited by: Immunology Physiology Immunology and Allergy
Partner nations: United Kingdom United States Sweden

In The Last Decade

Rainard Fuhr

53 papers receiving 1.4k citations

Hit Papers

align trajectories log scale

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

2019 mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials

Peers

Countries citing papers authored by Rainard Fuhr

Since Specialization

Citations

This map shows the geographic impact of Rainard Fuhr's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rainard Fuhr with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rainard Fuhr more than expected).

Fields of papers citing papers by Rainard Fuhr

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rainard Fuhr. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rainard Fuhr. The network helps show where Rainard Fuhr may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Rainard Fuhr, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Rainard Fuhr Line = papers co-authored together Rainard Fuhr links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Vericiguat: A Randomized, Phase Ib, Placebo-Controlled, Double-Blind, QTc Interval Study in Patients with Chronic Coronary Syndromes M. Böttcher,Hans‐Dirk Düngen,Vasile Corcea,Frank Donath,Rainard Fuhr,Pim Gal,Gerd Mikus,Dietmar Trenk,Martin Coenen,Philippe Vieira Pires,Claudia Maschke,Antonios O. Aliprantis,Nina Besche,Corina Becker	2023	9
2	A Phase 1/2, Open-Label, Multiple Ascending Dose Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INZ-701 in Adults with ENPP1 Deficiency Robert A. Wermers,Rainard Fuhr,Dirk Schnabel,Terra Arnason,Alix Bensacon,Borut Čižman,Deborah Wenkert,Yves Sabbagh,Kurt C. Gunter	2023	0
3	Nanoparticle-based oral formulation can surprise you with inferior in vivo absorption in humans Mayank Singhal,Elina Turunen,Tuula Ahtola-Sätilä,John Aspegrén,J. Raymond Bratty,Rainard Fuhr,K. Ojala,Bert van Veen,Leena Peltonen	2022	4
4	Diurnal variation in DLCO and non-standardized study procedures may cause a false positive safety signal in clinical trials Krishna Tulasi Kirla,Szilárd Nemes,Joanne Betts,Cecilia Kristensson,John Mo,Sara Asimus,Muhammad Waqas Sadiq,Elke Redlich,Thomas Koernicke,Rainard Fuhr,Wayne Brailsford,Christina Keen,Anette Hagberg,Jukka Mäenpää	2021	0
5	Safety, Tolerability and Pharmacokinetics (PK) of AZD8154, A Selective PI3Kγδ Inhibitor, After Single and Multiple Ascending Inhaled Doses in Healthy Volunteers Sara Asimus,Waqas Muhammad Sadiq,Cecilia Kristensson,Anette Hagberg,Jukka Mäenpää,Rainard Fuhr,Thomas Koernicke,Sofia Necander,Tina Jellesmark Jensen,Szilárd Nemes,Christina Keen,Wayne Brailsford,Joanne Betts	2020	2
6	mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trialsbreakdown → Robert Feldman,Rainard Fuhr,Igor Smolenov,Amilcar Ribeiro,Lori Panther,Michael Watson,Joseph J. Senn,Mike Smith,Örn Almarsson,Hari Pujar,Michael E. Laska,James D. Thompson,Tal Zaks,Giuseppe Ciaramella	2019	331
7	Efficacy and safety of AZD7594, an inhaled non-steroidal selective glucocorticoid receptor modulator, in patients with asthma: a phase 2a randomized, double blind, placebo-controlled crossover trial Mary N. Brown,Rainard Fuhr,Jutta Beier,Hong‐Lin Su,Yingxue Chen,Henrik Forsman,Ulrika Wählby Hamrén,Helen C. Jackson,Ajay Aggarwal	2019	20
8	Safety, pharmacokinetics and dose-response characteristics of GSK2269557, an inhaled PI3Kδ inhibitor under development for the treatment of COPD Anthony Cahn,J. Hamblin,Malcolm Begg,Robert C. Wilson,L. Dunsire,Srividya Sriskantharajah,Mickaël Montembault,Claudia Leemereise,Laura Galinanes-Garcia,Henrik Watz,Anne‐Marie Kirsten,Rainard Fuhr,Edith M. Hessel	2017	60
9	Pharmacokinetics of indacaterol and mometasone furoate delivered alone or in a free or fixed dose combination in healthy subjects Soniya Vaidya,Sanjeev Khindri,Nicole Calder,Surendra Machineni,Hisanori Hara,Tapan Majumdar,Salvatore Febbraro,Rainard Fuhr,Ralph Woessner	2016	14
10	Equivalent Lung Dose and Systemic Exposure of Budesonide/Formoterol Combination via Easyhaler and Turbuhaler Satu Lähelmä,Ulla Sairanen,Jussi Haikarainen,Jani Korhonen,Mikko Vahteristo,Rainard Fuhr,Merja Kirjavainen	2015	25
11	A Randomized, Phase I Pharmacokinetic Study Comparing SB2 and Infliximab Reference Product (Remicade®) in Healthy Subjects Donghoon Shin,Youngdoe Kim,Yoo Seok Kim,Thomas Körnicke,Rainard Fuhr	2015	55
12	Safety, tolerability and pharmacokinetics of QAV680, an oral CRTh2 antagonist, in healthy subjects Veit J. Erpenbeck,Rainard Fuhr,Gerald Dubois,Sheryl Perry	2014	0
13	Pharmacokinetics (PK) of indacaterol acetate and mometasone furoate delivered alone or in combination following once daily inhalation in healthy subjects Rainard Fuhr,Soniya Vaidya,Sanjeev Khindri,Nicole Calder,Surendra Machineni,Salvatore Febbraro,Ralph Woessner	2014	1
14	Abediterol (LAS100977), a novel long-acting β2-agonist: Efficacy, safety and tolerability in persistent asthma Jutta Beier,Rainard Fuhr,Èric Massana,E. Jiménez,Beatriz Seoane,Gonzalo de Miquel,Sandrine Ruiz	2014	13
15	Abediterol in stable asthma:efficacy, safety and tolerability results from a Phase II, randomised, crossover study Jutta Beier,Rainard Fuhr,Beatriz Seoane,Èric Massana,Gonzalo de Miquel,Helena Pujol,Sandrine Ruiz	2014	3
16	Omalizumab in patients with allergic (IgE-mediated) asthma and IgE/bodyweight combinations above those in the initially approved dosing table Oliver Kornmann,Henrik Watz,Rainard Fuhr,Norbert Krug,Veit J. Erpenbeck,Guenther Kaiser	2014	27
17	Clinical Assessment of Potential Drug Interactions of Faldaprevir, a Hepatitis C Virus Protease Inhibitor, With Darunavir/Ritonavir, Efavirenz, and Tenofovir John P. Sabo,Jens Kort,C. Ballow,Manuel Haschke,Manuel Battegay,Rainard Fuhr,B. Girlich,Michael J. Schobelock,U. Feifel,Benjamin Lang,Ye Li,M. Elgadi	2014	5
18	Efficacy of apolipoprotein B synthesis inhibition in subjects with mild-to-moderate hyperlipidaemia Fatima Akdim,Diane L. Tribble,JoAnn Flaim,Rosie Z. Yu,John Q. Su,Richard S. Geary,Brenda F. Baker,Rainard Fuhr,Mark K. Wedel,John J.P. Kastelein	2011	102
19	Efficacy and Safety of Twice-Daily Aclidinium Bromide 400 μ g Compared With Placebo and Tiotropium 18 μ g QD in Moderate to Severe COPD Patients Rainard Fuhr,H Magnussen,Anna Feliu,Anne‐Marie Kirsten,Meritxell Falqués,Cynthia Caracta,Esther García Gil	2010	3
20	Exploring the Relationship Between Expression of Cytochrome P450??Enzymes and Gefitinib Pharmacokinetics Helen Swaisland,Mireille Cantarini,Rainard Fuhr,Alison Holt	2006	56

About Rainard Fuhr

Rainard Fuhr is a scholar working on Immunology and Allergy, Physiology and Pulmonary and Respiratory Medicine, having authored 57 papers that have together received 1.5k indexed citations. Recurring topics across this work include Asthma and respiratory diseases (20 papers), Respiratory and Cough-Related Research (10 papers), Biosimilars and Bioanalytical Methods (9 papers), Pharmaceutical studies and practices (8 papers), Inhalation and Respiratory Drug Delivery (7 papers), Allergic Rhinitis and Sensitization (6 papers), Chronic Obstructive Pulmonary Disease (COPD) Research (5 papers) and Pharmacological Effects and Assays (5 papers). The work is most often cited by research in Immunology (453 citations), Physiology (331 citations) and Immunology and Allergy (63 citations). Rainard Fuhr has collaborated with scholars based in United Kingdom, United States and Sweden. Frequent co-authors include James D. Thompson, Tal Zaks, Hari Pujar, Mike Smith, Lori Panther, Igor Smolenov, Michael Watson, Joseph J. Senn, Robert Feldman and Giuseppe Ciaramella.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact